Completed PHASE4 INTERVENTIONAL 1-arm NCT03332511

Efficacy and Safety of Nilotinib in CML-CP (ENESTKorea)

A Phase 4 Study of Nilotinib in Korean Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase

Sponsor: Novartis Pharmaceuticals

Conditions Chronic Myeloid Leukemia, Chronic Phase

Interventions Nilotinib

Updated 5 times since 2017 Last updated: Nov 1, 2017 Started: May 6, 2013 Primary completion: Oct 24, 2016 Completion: Oct 24, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Chronic Myeloid Leukemia, Chronic Phase and is currently completed. Novartis Pharmaceuticals leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Dec 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals
Seoul National University Hospital

Data source: Seoul National University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.